AAP
UTMD icon

Arax Advisory Partners’s Utah Medical Products UTMD Stock Holding History

Arax Advisory Partners’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49K Buy
24
+9
+60% +$567 ﹤0.01% 3191
2025
Q4 		$840 Sell
15
-866
-98% -$50.2K ﹤0.01% 3524
2025
Q3 		$55.5K Buy
+881
New +$52.1K ﹤0.01% 1782
2024
Q4 		– Sell
-130
Closed -$8.7K – 2755
2024
Q3 		$8.7K Hold
130
– – ﹤0.01% 1479
2024
Q2 		$8.69K Buy
+130
New +$8.85K ﹤0.01% 1338

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's UTMD Position: Q1 2026 in Review

Arax Advisory Partners increased its Utah Medical Products (UTMD) stake by 60% in Q1 2026, buying an estimated $567 and bringing the position to 24 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3191.

Arax Advisory Partners first reported a position in UTMD in Q2 2024 and has held it in 5 quarters since. The position peaked at $55.5K in Q3 2025. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Arax Advisory Partners held 24 shares of Utah Medical Products worth $1.49K as of Q1 2026.
  • Arax Advisory Partners bought 9 Utah Medical Products shares in Q1 2026, an estimated $567.
  • Utah Medical Products made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3191 holding.
  • Arax Advisory Partners first reported a position in Utah Medical Products in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Utah Medical Products position peaked at $55.5K in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.